Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trialsCathrine Axfors, Bryan J. McVerry, Andreas M. Schmitt et al.|Nature Communications|2021Cited by 295
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – Preliminary reportChristopher W. Seymour, Rashan Haniffa, Alisa M. Higgins et al.|medRxiv|2021Cited by 137
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trialYaseen M. Arabi, Anthony Gordon, Lennie Derde et al.|Intensive Care Medicine|2021Cited by 100
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trialsCathrine Axfors, Bryan J. McVerry, Andreas M. Schmitt et al.|medRxiv|2020Cited by 79
The impacts of New Zealand's COVID-19 epidemic response on community antibiotic use and hospitalisation for pneumonia, peritonsillar abscess and rheumatic feverEamon Duffy, Stephen Ritchie, Mark Thomas et al.|The Lancet Regional Health - Western Pacific|2021Cited by 17